<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04968912</url>
  </required_header>
  <id_info>
    <org_study_id>CR109062</org_study_id>
    <secondary_id>2021-000665-32</secondary_id>
    <secondary_id>80202135SJS2001</secondary_id>
    <nct_id>NCT04968912</nct_id>
  </id_info>
  <brief_title>A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of nipocalimab in&#xD;
      participants with primary Sjogren's syndrome (pSS) versus placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sjogren's syndrome is a chronic, progressive autoimmune disease of unclear etiology typically&#xD;
      originating in exocrine glands and capable of affecting the function of almost any organ&#xD;
      system in the body. Nipocalimab is a fully human aglycosylated immunoglobulin (Ig)G1&#xD;
      monoclonal antibody designed to selectively bind, saturate, and block the IgG binding site on&#xD;
      the endogenous neonatal fragment crystallizable receptor (FcRn). Nipocalimab blocks the&#xD;
      binding site for IgG on FcRn, leads directly to increased IgG catabolism and a decrease in&#xD;
      circulating IgG antibody concentrations, including pathogenic IgG antibody concentrations,&#xD;
      and directly inhibits inflammatory cellular responses to these pathogenic IgG. Therefore,&#xD;
      Nipocalimab may successfully treat pSS and improve disease manifestations. The study will&#xD;
      consist of Screening Period (less than or equal to [&lt;=] 6 Weeks), Double-blind Treatment&#xD;
      Period (24 Weeks), and a Follow-up Period (6 Weeks). Key safety assessments will include&#xD;
      adverse events (AEs), serious adverse events (SAEs), adverse events of special interests&#xD;
      (AESIs), clinical laboratory safety tests (hematology, chemistry, urinalysis, and lipid&#xD;
      profile) and vital signs. The total duration of the study is up to 36 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (clinESSDAI) Score at Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The clinESSDAI is a validated tool used in clinical studies to measure the systemic disease activity in participants with primary Sjogren's syndrome. The clinESSDAI includes 11 domains divided into 3-4 activity levels, where zero represents no activity and low, medium, and high scores can vary in numerical value depending on the domain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in European League Against Rheumatism (EULAR) Sjogren Syndrome Patient Reported Index (ESSPRI) Score at Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The ESSPRI is a patient-reported assessment of the severity of dryness, fatigue, and pain associated with primary Sjogren's Syndrome. Participants are asked to rate the severity of dryness, fatigue and pain over the past 2 weeks on a numeric rating scale (NRS), ranging from 0 &quot;no symptoms (dryness, fatigue or pain)&quot; to 10 &quot;maximal imaginable (dryness, fatigue, pain)&quot;. A global score, calculated as the mean of the 3 domain scores, ranges from 0 to 10, with higher scores reflecting greater (worse) symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Greater than or Equal to (&gt;=) 4 Points from Baseline in ESSDAI Score (Minimal Clinically Important Improvement) at Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The ESSDAI is a validated tool used in clinical studies to measure the systemic disease activity in participants with primary Sjogren's syndrome. The ESSDAI includes 11 to 12 domains divided into 3-4 activity levels, where zero represents no activity and low, medium, and high scores can vary in numerical value depending on the domain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of &gt;= 4 Points from Baseline in clinESSDAI Score (Minimal Clinically Important Improvement) at Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The clinESSDAI is a validated tool used in clinical studies to measure the systemic disease activity in participants with Sjogren's syndrome. A minimal clinically important improvement in clinESSDAI is defined as a decrease of at least 4 points in the composite clinESSDAI score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ESSPRI Response at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>ESSPRI response defined as a decrease of one point or a decrease of &gt;= 15 percent (%) from baseline (minimal clinically important improvement) at Week 24 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sjogren's Syndrome Responder Index (SSRI) Response at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>SSRI response defined as &gt;= 20% improvement from baseline in at least two of five domains (fatigue, oral dryness, ocular dryness, unstimulated whole salivary flow, erythrocyte sedimentation rate) at Week 24 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Disease Activity Level by &gt;= 1 Level in at Least One clinESSDAI or ESSDAI Domain at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Improvement in disease activity level by &gt;= 1 level in at least one clinESSDAI or ESSDAI domain (biological, hematological, cutaneous, constitutional, lymphadenopathy and lymphoma, and glandular) at Week 24 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement from Baseline in &gt;= 3 of 5 Composite of Relevant Endpoints for Sjogren's Syndrome (CRESS) Categories at Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Improvement from baseline in &gt;= 3 of 5 CRESS categories at week 24 will be reported. CRESS is a composite tool that incorporates measures of disease activity (clinESSDAI), symptoms (ESSPRI), glandular function and systemic inflammation to assess disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events of Special interests (AESIs)</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>Percentage of participants with AESIs will be reported. Treatment-emergent adverse events associated with the following situations are considered as AESIs: severe infections, severe hypoalbuminemia or hypogammaglobulinemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Treatment-emergent Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>Treatment-emergent SAEs are defined as SAEs with onset or worsening on or after date of first dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Clinically Significant Abnormalities in Vital Signs</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>Percentage of participants with clinically significant abnormalities in vital signs (including temperature, pulse/heart rate, respiratory rate, and blood pressure) through end of study visit will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Clinically Significant Abnormalities in Laboratory Parameters</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>Percentage of participants with clinically significant abnormalities in laboratory parameters (including hematology, blood chemistry, urinalysis, and blood coagulation) through end of study visit will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Nipocalimab Over Time</measure>
    <time_frame>Up to Week 30</time_frame>
    <description>Serum concentrations of nipocalimab over time in participants receiving active study intervention will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Antibodies to Nipocalimab (Anti-drug Antibodies [ADAs] and Neutralizing Antibodies [NAbs])</measure>
    <time_frame>Up to Week 36</time_frame>
    <description>Number of participants with antibodies to nipocalimab (ADAs and NAbs) in participants receiving active study intervention will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Change from Baseline in Biomarkers</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>Number of participants with change from baseline in biomarkers (C-reactive protein [CRP], erythrocyte sedimentation rate [ESR], total immunoglobulin [Ig]G, IgG1, IgG2, IgG3, IgG4) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Change from Baseline in Autoantibodies</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>Number of participants with change from baseline in autoantibodies (anti-Sjogren's syndrome related antigen A (anti-Ro/SSA), anti-Sjogren's syndrome related antigen B (anti-La/SSB), rheumatoid factor [RF] and antinuclear antibody [ANA]) will be reported.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Sjogren's Syndrome</condition>
  <arm_group>
    <arm_group_label>Group 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo intravenously (IV) every 2 weeks (q2w) through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Nipocalimab Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive nipocalimab dose 1 IV q2w through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Nipocalimab Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive nipocalimab dose 2 IV q2w through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo infusion will be administered intravenously.</description>
    <arm_group_label>Group 1: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nipocalimab</intervention_name>
    <description>Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.</description>
    <arm_group_label>Group 2: Nipocalimab Dose 1</arm_group_label>
    <arm_group_label>Group 3: Nipocalimab Dose 2</arm_group_label>
    <other_name>JNJ-80202135</other_name>
    <other_name>M281</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care Treatment</intervention_name>
    <description>Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.</description>
    <arm_group_label>Group 1: Placebo</arm_group_label>
    <arm_group_label>Group 2: Nipocalimab Dose 1</arm_group_label>
    <arm_group_label>Group 3: Nipocalimab Dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meets classification criteria for primary Sjogren's syndrome (pSS) by the 2016&#xD;
             American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR)&#xD;
             within 5 years but at least 6 months prior to screening&#xD;
&#xD;
          -  At screening is seropositive for antibodies to pSS-associated antigen A (60 kilodalton&#xD;
             [kDa] Ro/Sjogren's syndrome-related antigen A [SSA])&#xD;
&#xD;
          -  Total Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity&#xD;
             Index (clinESSDAI) score greater than or equal to (&gt;=) 6 and less than or equal to&#xD;
             (&lt;=) 13&#xD;
&#xD;
          -  At least low activity as defined in the biological domain of European League Against&#xD;
             Rheumatism (EULAR) and in at least low activity in at least one of the following&#xD;
             ESSDAI domains: cutaneous, articular, glandular, constitutional, hematologic, and&#xD;
             lymphadenopathy&#xD;
&#xD;
          -  It is recommended that participants are up to date on all age-appropriate vaccinations&#xD;
             prior to screening as per routine local medical guidelines. For study participants who&#xD;
             received locally-approved (and including emergency use-authorized) coronavirus disease&#xD;
             2019 (COVID-19) vaccines recently prior to study entry, applicable local vaccine&#xD;
             labelling, guidelines, and standards-of-care for participants receiving&#xD;
             immune-targeted therapy will be followed when determining an appropriate interval&#xD;
             between vaccination and study enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has any confirmed or suspected clinical immunodeficiency syndrome not related to&#xD;
             treatment of his/her pSS or has a family history of congenital or hereditary&#xD;
             immunodeficiency unless confirmed absent in the participant&#xD;
&#xD;
          -  Comorbidities (for example, asthma, chronic obstructive pulmonary disease) which have&#xD;
             required 3 or more courses of systemic glucocorticoids within the previous 12 months&#xD;
&#xD;
          -  Has any unstable or progressive manifestation of pSS that is likely to warrant&#xD;
             escalation in therapy beyond permitted background medications and/or has severely&#xD;
             active pSS (clinESSDAI score greater than [&gt;] 13)&#xD;
&#xD;
          -  Has received oral cyclophosphamide within 3 months or intravenous (IV)&#xD;
             cyclophosphamide within 6 months prior to first administration of study intervention&#xD;
&#xD;
          -  Has Sjogren's syndrome overlap syndromes where another confirmed autoimmune rheumatic&#xD;
             or systemic inflammatory condition (for example, rheumatoid arthritis [RA], systemic&#xD;
             lupus erythematosus [SLE], scleroderma, inflammatory bowel disease [IBD]) is the&#xD;
             primary diagnosis or has clinical manifestations that, in the opinion of the&#xD;
             investigator, are likely to interfere with the investigator's ability to assess pSS&#xD;
             manifestations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Arthritis and Rheumatology Research, PLLC</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Research, PLLC</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Jude Heritage Medical Group</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inland Rheumatology Clinical Trials, Inc.</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colorado Arthritis Associates</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Denver Arthritis Clinic</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre for Rheumatology, Immunology and Arthritis</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omega Research Consultants</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Investigation Specialists</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Paul Rhuematology, P.A.</name>
      <address>
        <city>Eagan</city>
        <state>Minnesota</state>
        <zip>55121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Clinics</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>PMG Research of Salisbury</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Altoona Center For Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Reading Hospital</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Tennessee Research Institute</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Ramesh Gupta</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Regional Clinic</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731-3146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trinity Clinical Research, LLC</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arthritis Northwest PLLC</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Hôpital Albert Michallon</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Le Mans</name>
      <address>
        <city>le mans Cedex 9</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Joseph</name>
      <address>
        <city>Marseille Cedex 08</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Havre</name>
      <address>
        <city>Montivilliers</city>
        <zip>76290</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hamburger Rheuma Forschungszentrum II</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>medius KLINIK KIRCHHEIM</name>
      <address>
        <city>Kirchheim unter Teck</city>
        <zip>73230</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln</name>
      <address>
        <city>Köln</city>
        <zip>50923</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Presidio Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>P.O. Vittorio Emanuele Azienda Ospedaliero Universitaria 'Policlinico Vittorio Emanuele'</name>
      <address>
        <city>Catania</city>
        <zip>95100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone</name>
      <address>
        <city>Palermo</city>
        <zip>90129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata Verona</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital</name>
      <address>
        <city>Nagasaki</city>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo-shi</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Luke's International Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nihon University Itabashi Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Tsukuba Hospital</name>
      <address>
        <city>Tsukuba-Shi</city>
        <zip>305-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz Przychodnie Medyczne</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-065</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki nr 2 im. dr. Jana Biziela w Bydgoszczy</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Kliniczno Badawcze J. Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka Partnerska</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>REUMED Zespol Poradni Specjalistycznych Filia nr 2</name>
      <address>
        <city>Lublin</city>
        <zip>20-607</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne</name>
      <address>
        <city>Poznan</city>
        <zip>61-113</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medycyna Kliniczna</name>
      <address>
        <city>Warsaw</city>
        <zip>00-874</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne AMED Warszawa Targowek</name>
      <address>
        <city>Warszawa</city>
        <zip>03-291</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Oporow</name>
      <address>
        <city>Wrocław</city>
        <zip>52-415</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues de Reumatologia</name>
      <address>
        <city>Lisboa</city>
        <zip>1050-034</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ULSAM, EPE - Hospital Conde de Bertiandos</name>
      <address>
        <city>Ponte de Lima</city>
        <zip>4990-078</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.</name>
      <address>
        <city>Vila Nova de Gaia</city>
        <zip>4434-502</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. de La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. A Coruña</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hosp. de Merida</name>
      <address>
        <city>Mérida</city>
        <zip>6800</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitari Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinico Univ. de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Infanta Luisa</name>
      <address>
        <city>Sevilla</city>
        <zip>41010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital Linkou Branch</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR109062</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 9, 2021</study_first_submitted>
  <study_first_submitted_qc>July 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

